Ping An Good Doctor Soars Over 15% in Stock Price, Reaching a 4-Year High, with Revenue and Profit Growth Accelerating!
Glorious 8th August | Ping An Good Doctor (1833.HK) surged during the trading session, once rising over 15%, to HKD 18.2, reaching a new high since October 2021, with a transaction volume of HKD 7.2 billion as of now.
On the news front, in the field of internet healthcare, on August 20th, Premier Li Qiang, member of the Central Political Bureau and Chairman of the State Council, emphasized during his research visit to Beijing that it is crucial to leverage artificial intelligence to empower industry development, thereby improving the intelligentization levels of pharmaceutical research and development, clinical trials, diagnosis, treatment, and production logistics.
On a company level, Ping An Good Doctor announced its performance results on August 19th evening, showing that revenue for the first half of 2025 reached HKD 2.5 billion, with a year-on-year growth of 19.5%; net profit attributable to shareholders was HKD 134 million, with a year-on-year growth of 136.8%; and approximately 24 million paying users, with a year-on-year growth of 35.1%.
After announcing its performance results, the company released a performance review stating that Ping An Good Doctor's first-half performance is impressive, with its stock price's strong performance attributed to its progress in AI healthcare and improved profit prospects. The company expects the development of AI healthcare and commercial health insurance to drive further growth, revising its target price from HKD 10 to HKD 20, reaffirming its "outperform" rating. Lyon also believes that Ping An Good Doctor is a major beneficiary of China's AI healthcare and commercial health insurance development, two trends gaining increasing attention in the Chinese healthcare industry. Given the company's optimistic performance, Lyon has revised its revenue forecast for 2025-2027 to HKD 1.9% to 5.6%, based on more optimistic profit assumptions. Lyon also expects the market's enthusiasm for AI healthcare companies to remain unchanged, as the cycle of technology investment and potential AI-driven applications continues to gain momentum.